Trichostatin A (TSA) 化学構造
分子量: 302.4

高品質保証

カスタマーフィードバック(4)

MSDS

製品説明

  • Compare HDAC Inhibitors
    HDAC製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法
  • Trichostatin A (TSA)のメカニズム

製品の説明

生物活性

製品説明 Trichostatin A (TSA)は一種のHDAC阻害剤で、無細胞試験でIC50値が1.8 nM程度です。
ターゲット

HDAC

IC50

~1.8 nM [1]

In vitro試験 Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. [1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. [2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HEK 293 M4KzSWZ2dmO2aX;uJGF{e2G7 NFPRSogxNjgQvF2= M4DaTFI1cA>? NWPYXoJt\XSqYX7vcC=> NUn2b|Nt\W6qYX7j[ZMhTU6jQzDhZ4V1gWyjdHnvckBidmRiaX7jdoVie2W|IFXOZWMh[WK3bnThcoNmKGmwIITo[UB1d3SjbDDj[YxtKGy7c3H0[UBidmRiYYSgeIhmKGOnbHygd5Vz\mGlZR?= NFrifmMzPTd6N{C3PS=>
TE13 M1zT[2Z2dmO2aX;uJGF{e2G7 NX60V4JCOC5|zszN M4\HelI1cA>? NUTUOVBnfXBvcnXneYxifGW|IGLBV3NHPUFibHX2[Yw> MVKyOVU4QTZ4NR?=
TE13 NISwOFVCeG:ydH;zbZMhSXO|YYm= NFPGWpExNjQQvF2= NWHDOI9kOjSq NWfOfXY6cW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbh?= NEHkS2QzPTV5OU[2OS=>
MEFs M4rZbGZ2dmO2aX;uJGF{e2G7 NVvTNotVPc7:TR?= NX\BTGhxOT[q M2nrVolv[3KnYYPld{B1cGViRWDFR{BifHSjY3jt[Y51NCCWaYKg[IVtcX[ncomgZY5lKHSqZTDl[oZq[2mnbnP5JI9nKHCnZHXzeIFtKG[xcn3heIlwdg>? M1jsXlI2PDh{NkO0
SW480  M{nEUmZ2dmO2aX;uJGF{e2G7 MYSwMlHPxE1? NV\ufJM6PDiq NWHsOFQxTE2VTx?= M3Xhd5JmfmW{c3XzJGVOXA>? MYKyOVQ{PDl7Nx?=
PC3  M2HkPWZ2dmO2aX;uJGF{e2G7 MXmwMlHPxE1? NYP4d4VFPDiq M2npemROW09? NGjoUm1z\X[ncoPld{BGVVR? MVqyOVQ{PDl7Nx?=
SW480  MoHPSpVv[3Srb36gRZN{[Xl? NEfOXWQxNjIQvF2= NHLFd2Y1QGh? MnTMSG1UVw>? MX\heJRmdnWjdHXzJIlvfmG|aX;uJIFv\CCvaXfyZZRqd25? NXLBWnh7OjV2M{S5PVc>
PC3  NEPKbXdHfW6ldHnvckBCe3OjeR?= NVH0U4h6OC5zzszN M1fEbVQ5cA>? MXjEUXNQ MV7heJRmdnWjdHXzJIlvfmG|aX;uJIFv\CCvaXfyZZRqd25? M3y4blI2PDN2OUm3
SW480  M1fKbGZ2dmO2aX;uJGF{e2G7 Mn7NNE4y|ryP NFvqd3Q1QGh? NEHzN3FFVVOR MlPSbY5lfWOnczDpcoNz\WG|ZTDv[kBJTEGFMTDhcoQhUESDQ{Kgc44hW2y3ZzDn[Y5meyCycn;tc5Rmeg>? NHnzUYczPTR|NEm5Oy=>
PC3  MXzGeY5kfGmxbjDBd5NigQ>? MV:wMlHPxE1? Ml\3OFhp MnTISG1UVw>? MlT0bY5lfWOnczDpcoNz\WG|ZTDv[kBJTEGFMTDhcoQhUESDQ{Kgc44hW2y3ZzDn[Y5meyCycn;tc5Rmeg>? MYWyOVQ{PDl7Nx?=
A431 M1TiWmFxd3C2b4Ppd{BCe3OjeR?= MojQNk8yOC93MD:xNFBvVQ>? MXG0PIg> NVPGWINVTE2VTx?= NVfKVW1zcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4To M4rOblI2OzdzME[5
A431 MX\GeY5kfGmxbjDBd5NigQ>? M33KVFUxdk1? NV75PZZpOi94L{GyM|I1cA>? NH:5NGZFVVOR NFTwN4pi[3SrdnH0[ZMheDJzIHHu[EBqdmirYnn0d{BCXEZ|IHX4dJJme3Orb36= MXiyOVM4OTB4OR?=
MDA-MB-231 NHi2R5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnO5NE03ODCwTR?= NHf1W3EzPGh? NGizboxFVVOR M3TOdmlEPTBib3[gNVAxdk1? MV2yOVE6Ojd{MR?=
MCF7 M4r1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYiwMVYxOG6P MWOyOIg> NGrVS3pFVVOR MV\JR|UxKG:oIEe1cm0> MVuyOVE6Ojd{MR?=
SKOV-3 MnjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1focFEuOTEQvF2= MlzTNlRp M4Dpb2ROW09? NYW4WmFnUUN3MDDv[kA2NjcQvF2= M2jHdFI2OTZ7NEmx
A549 MnXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXz5fmlLOS1zMN88US=> M1foXlI1cA>? Mon1SG1UVw>? NXLRVo9MUUN3MDDv[kA{NjMQvF2= MoTUNlUyPjl2OUG=
SKOV-3 NEjCd3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVmwMlEuOc7:TR?= M{HTWFQ5cA>? MknHSG1UVw>? M1fpZ2lEPTBib3[gNE44|ryP M3K2b|I2OTZ7NEmx
A549 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\VRlAvOS1zzszN MnXhOFhp NXn5VnJLTE2VTx?= NF23bohKSzVyIH;mJFAvOjkQvF2= NFXTUpozPTF4OUS5NS=>
SKOV-3 NG\TcItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX:wMlAyNTBwOd88US=> NX;odZdZPzKq MoC0SG1UVw>? M2mzT2lEPTBib3[gNE4{Os7:TR?= NHTyOWwzPTF4OUS5NS=>
A549 NHPQOnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILFSVExNjBzLUCuPe69VQ>? MlvIO|Jp NF\yWoNFVVOR NWqxZ3RoUUN3MDDv[kAxNjB4zszN MkL4NlUyPjl2OUG=
HeLa M3vlVWZ2dmO2aX;uJGF{e2G7 M2XXZVI2OG6P MXexOog> MlvrSG1UVw>? M4LPS4lv[3KnYYPld{BEYVBzQUGgcXJPSSCneIDy[ZN{cW:wwrC= MXmyOVEyPjZ6OB?=
CNE2 NILOfYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVv2eotvOTByLU[wNI5O MlPiNlQwPDhxN{Lo Mn7YbY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gbY4h[SC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M3\mUFI1QTZ7OUCx
PC3 NXWyR|RiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnoWJU{OTByLUGwNFBvVQ>? MXSyOIg> MUTJR|UxKG:oIEOwNI5O MXOyOFg2PDZ3OB?=
LNCaP MlzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4S0V|ExOC1zMECwcm0> NYL2cJdROjSq NWXyeINHUUN3MDDv[kA{ODCwTR?= MY[yOFg2PDZ3OB?=
HeLa  MnfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7lNu69VQ>? NVyyVWxsPDiq NV3iOWpx\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIFjd3W2IEK1KS=> MoLUNlQ5PDZzM{W=
HMEC-1  M{TC[mZ2dmO2aX;uJGF{e2G7 M4XHWVMxOG6P NIPIT44zPGh? NWDacGFrcW6lcnXhd4V{KGW6cILld5Nqd25ib3dCpHZGT0[UM9MgcXJPSQ>? Mo\CNlQ4OTB4M{G=
HeLa NY\hc3hxTnWwY4Tpc44hSXO|YYm= NWjObYw5OW2P NFK5O3MxNjWq MnXWZYJwdGm|aHXzJJRp\SC2b4ThcEBJTEGFIHHjeIl3cXS7 NI\nNpQzPDdyN{S3OC=>
ACP02 M1S5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV2yOVAwOzVyL{WwNI5O MkXyNlRp NGXre2Fl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgc4Yh[XCycn;4bY1ifGWueTC3NOKhLSCjdDCyOVDDqG6P MWqyOFY3QDV2Nx?=
ACP03 NXPIfYFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fTe|I2OC9|NUCvOVAxdk1? NXTWfW9iOjSq MkjC[IVkemWjc3XzJINmdGxidnnhZoltcXS7IH;mJIFxeHKxeHntZZRmdHliN{FCpEUh[XRiMkWwxsBvVQ>? Mmj5NlQ3Pjh3NEe=
U87 GBM MlSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrVeXRLOTByL{OwNE82ODBibl2= MYK3NkBp M{[5W|ExOCViZYToZY5wdA>? M3foUJJm\HWlZYOgcYVidiClZXzsJI52dWKncjDifUA{OSxiNUSsJIFv\CB3ONMgKS=> MWGyOFQ3PDh2MR?=
U87 GBM MW\GeY5kfGmxbjDBd5NigQ>? MYOxNFAwPTByIF7t MV[0PEBp MVyxNFAmKGW2aHHuc4w> M1XsTWlv\HWlZYOgV4Vv\XOlZX7j[U1NcWunIFHseIVz[XSrb37zJIlvKE63Y3zlZZIhVW:{cHjvcI9ogQ>? Ml7CNlQ1PjR6NEG=
RPE MkDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUGwMlIwOC52L{CuPE8yKM7:TR?= NHXHTFUzPC92OD:3NkBp NYHPdZFWTE2VTx?= NV\OcocycW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44h[nliY3XscEBkgWOuZTDhdpJme3R? M{D5WFI1PDV4NkCy
HT29  MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXOxPFAhdk1? NY\3eGxjPzJiaB?= MUPJR|UxKG:oIEG4NEBvVQ>? NIfncWozPDN4OEK2OS=>
hMSCs NYCxVI9TTnWwY4Tpc44hSXO|YYm= M4\5U|YvOjVibl2= NILV[ZMzPCCq MnTpSG1UVw>? MXXzeIFjcWyrenXzJGhqe3SxbnWgRYNmfHmuYYTpc44h[W6mIITo[UBGgHC{ZYPzbY9vKG:oIGDseZJqeG:2ZX70JGdmdmW| MXWyOFMyOjN3Nh?=
Huh7  MnHISpVv[3Srb36gRZN{[Xl? NXzoTpFwOC5zL{CuOU8yNjBizszN NV7YdWZGOjSq Mn3Md5VxeHKnc4Pld{B[XEiGQ{Kg[4Vv\SCneIDy[ZN{cW:w M{fzV|I1OjZ7Nkey
SKOV3 NYW3bnh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPrNE4xPS1{IN88US=> MkfsNVAwOjRxNEigbC=> NUTzVmE3TE2VTx?= NYLuO3Y1dWWmaXH0[ZMh\3Kxd4ToJIFzemW|dDDpckBiKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NIHTc5ozPDJ{M{iwNS=>
A2780 M3\Temdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY[wMlA2NTJizszN NH7OOlYyOC9{ND:0PEBp MYfEUXNQ NF\yS|Zu\WSrYYTld{Boem:5dHigZZJz\XO2IHnuJIEh[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= M3Twb|I1OjJ|OECx
SRA01/04  M2\2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLldoFUOC5{IN88US=> Mme0OFghcA>? M1jzZ2ROW09? M{TOcZN2eHC{ZYPz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKHSqcn;1[4ghe3WycILld5NqdmdidHjlJHBKO0txQXv0MEBxOziPQWDLJIFv\CCHUluxM|Ihe2mpbnHsbY5oKHCjdHj3ZZl{ MkK3NlQyPTd6N{i=
HLEB3 NF\ndZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYqwMlIh|ryP NFK5W4o1QCCq NVfMZ3JXTE2VTx?= NIriUHZ{fXCycnXzd4V{KGOnbHygdJJwdGmoZYLheIlwdiC2aILveYdpKHO3cIDy[ZN{cW6pIITo[UBRUTONL1HreEwheDN6TVHQT{BidmRiRWLLNU8zKHOrZ37hcIlv\yCyYYToe4F6ew>? MlPtNlQyPTd6N{i=
SRA01/04  M2n4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWiwMlQwOC56IN88US=> M3POXlQ5KGh? M17p[WROW09? M1K4bIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M4fmdVI1OTV5OEe4
HLEB3 NFy3XIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTCNE41NzBwODFOwG0> MkS2OFghcA>? NX\lNmxSTE2VTx?= M{nmRolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M1yzfVI1OTV5OEe4
HCT116 NEC2emxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHpZ40xNjJizszN MYGxNkBp MUHlcohidmOnczDj[YxtKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IILh[IlifGmxbh?= M1LVblI1OTJ{MkOx
CA46 MmjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkixN{83NzF{L{K0M|Q5KG6P M4jOc|Q5KGh? MW\pcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGG2IEK0JIFv\CB2ODDuUeKh M33GdVI1ODZ2OUWx
PMNs MlXsSpVv[3Srb36gRZN{[Xl? NX;ZVJRGOzBibl2= NIXoNY01QCCq MXXpcohq[mm2czDl[oZmem:leYTvd4l{NCCKRFHDJIFkfGm4aYT5JIFv\CCUYXOgZYN1cX[rdIm= NWXq[4ZmOjN7OEi2NVc>
H1299 MlXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPPTVU{OcLizszNxsA> MYGyOE81QC95MjDo M{fMdYV1cGGwb3y= M1y3eYlv[3KnYYPld{Bk\WyuIHTlZZRpKGGodHXyJFI1cA>? NGDEeGszOzlzNk[wPS=>
A549 MoK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4X3TVAvOjVxMD61M|Eh|ryP MXiyOE81QC95MjDo M2DQPIV1cGGwb3y= MU\pcohq[mm2czD0bIUh[2WubDDndo94fGhiaX6gZ49v[2WwdILheIlwdiCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz Mkf3NlM5Pjd7OUG=
H1299 NXvnWoMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4[xblAvOjVxMD61M|Eh|ryP MUOyOE81QC95MjDo NYLDfplw\XSqYX7vcC=> NEH3d2FqdmirYnn0d{B1cGViY3XscEBoem:5dHigbY4h[2:wY3XueJJifGmxbjDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ Mm\KNlM5Pjd7OUG=
A549 NYPsWo54SXCxcITvd4l{KEG|c3H5 Mkm4NE42NzFizszN M2H4R|Q5KGh? NVzseIFt\XSqYX7vcC=> NVXYTG92cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M3nYVFI{QDZ5OUmx
H1299 MnrKRZBweHSxc3nzJGF{e2G7 NH;SVVkxNjVxMTFOwG0> NWfvTYRqPDhiaB?= MYnleIhidm:u MmXGbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MVuyN|g3Pzl7MR?=
SUM149PT MlHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLseJM4Oi95LkWvNVAh|ryP MlTsOFghcA>? NHXab4FFVVOR MmjsbY5lfWOnczDj[YxtKGSnYYToJIF1KDJizszNJIlve2Wwc3n0bZZmdHl? MkDrNlM4QTJ4M{i=
SUM190PT NEnNO|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVq1NE8yODBxMkWwJI5O MXG0PEBp M2TGdmROW09? NFzxbo5qdmS3Y3XzJINmdGxiZHXheIgh[XRiNUCgcm0he2Wwc3n0bZZmdHl? MnzGNlM4QTJ4M{i=
HCT1 NYm1e3RFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Lw[lAvOi9zLkCvOU4xKM7:TR?= MmG4NVIwOjRxM{[vOFghcA>? MVXpcoR2[2W|IHPlcIwh\GWjdHigbY4h[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= MoryNlM4PzByMEC=
Lovo M2W5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;J[IcxNjJxMT6wM|UvOCEQvF2= M2exVFEzNzJ2L{O2M|Q5KGh? NGHDco1qdmS3Y3XzJINmdGxiZHXheIghcW5iY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> MmLRNlM4PzByMEC=
AGS NXPnbFdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUCwMlAyPS1zIN88US=> M{GyU|czKGh? MmrZbY5lfWOnczDj[YxtKGSnYYToJINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm= M2PMO|I{PzR3MEK0
Huh7 M2jIfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3nU3B7OSEQvF2= NEG1VlEzPCCq MkfOSG1UVw>? NVTtfnFWemWmdXPld{Bi[m:3dDCyNEUhfmmjYnnsbZR6yqB? M2PDN|I{PjR|OUOz
ECC1 NULHV3g4TnWwY4Tpc44hSXO|YYm= MWC1NFAhdk1? Ml3KOUBl NVfyOZlrTE2VTx?= NX3tXZNjcW6mdXPld{BNOUODTdMg[ZhxemW|c3nvckBkdy22cnXheI1mdnRid3n0bEA2NUG8YVO= M4r2[lI{PTNyN{[5
HEC1A M{PwUGZ2dmO2aX;uJGF{e2G7 NXexToJvPTByIH7N NW\s[21PPSCm NV7Tb4NZTE2VTx?= MX;pcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? MnLnNlM2OzB5Nkm=
EN1 NFO2OIJHfW6ldHnvckBCe3OjeR?= MYi1NFAhdk1? M4fLNlUh\A>? MnzUSG1UVw>? MmDybY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN? M3X1d|I{PTNyN{[5
MFE296 MmGwSpVv[3Srb36gRZN{[Xl? M2Lwe|UxOCCwTR?= Mny3OUBl M{nJXWROW09? M3fm[Ilv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF NInLWJUzOzV|MEe2PS=>
HASMCs MY\GeY5kfGmxbjDBd5NigQ>? NVz6OYI1OC13MECgcm0> MU[2JIQ> M1TrdIRwf25vcnXneYxifGW|IITo[UBmgHC{ZYPzbY9vKG:oIFjBSGMh[W6mIHPlcIwhfmmjYnnsbZR6 MWCyN|UyQDR4Nx?=
U373 NVjBO4o6TnWwY4Tpc44hSXO|YYm= NXTVN|JEOC5{NT:wMlUwOSEQvF2= M1LSdFI1KGh? NYTVXYJzcW6lcnXhd4V{KFCULVKg[ZhxemW|c3nvckBkdy22cnXheI1mdnRid3n0bEA2SXqjZFO= MYmyN|Q4PDF5MR?=
ARN8  Mn60SpVv[3Srb36gRZN{[Xl? MV6wMlA2NTJizszN NUizVVVyOjRiaB?= Ml3xdoVlfWOnczD0bIUhcW6mdXP0bY9vKG:oIIC1N{1l\XCnbnTlcpQh\2WwZYOgZpkhVnW2bHnuMVM> NX21foFGOjN2N{C1OFA>
MCF7 NIjLV5NHfW6ldHnvckBCe3OjeR?= NX;5[lFoOC5yNT2yJO69VQ>? MojMNlQhcA>? MXTy[YR2[2W|IITo[UBqdmS3Y4Tpc44hd2ZicEWzMYRmeGWwZHXueEBo\W6nczDifUBPfXSuaX6tNy=> MlzuNlM1PzB3NEC=
H1299  NXW2NlRHTnWwY4Tpc44hSXO|YYm= NWHUfoM6OC5|M,MAl|HDqML3TR?= NEnMRZQzPC92ODDo NF7hUGtFVVOR M1frbIlv[3KnYYPld{BGNWOjZHjldolvKHC{b4TlbY4hdGW4ZXzzJIRwe2ViZHXw[Y5l\W62bIm= NWHDTmtGOjN2NkG5O|U>
H1299 NIjscW5HfW6ldHnvckBCe3OjeR?= MmXvNE42KM7:TR?= MoHNOFghcA>? MVfEUXNQ MW\pcohq[mm2czD0bIUhdWmpcnH0c5J6KHCxdHXueIlidCClb33ibY5mKHerdHigd4ltcWKrbnnu NWjYZ2c{OjN2NkG5O|U>
H1299 MWrGeY5kfGmxbjDBd5NigQ>? MX2wMlUh|ryP Ml3OOFghcA>? NVz6NHpNTE2VTx?= MlT6bY5pcWKrdIOgeIhmKGmwdnHzbZZmdmW|c9MgJINwdWKrbnWge4l1cCC|aXzpZolvcW5? MnjDNlM1PjF7N{W=
MG-63  NWrYR2p7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnviNE4{KM7:TR?= NGfX[JYyOi17NjDo MoHOSG1UVw>? NGjySZVqdmirYnn0d{B1cGViY3XscEBoem:5dHigZ48ufHKnYYTt[Y51KHerdHigcYV1\m:{bXnu MWGyN|Q2OThzNx?=
LM8 M4Xofmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvYPHExNjNizszN MXqxNk06PiCq MVTEUXNQ MoWwbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHPvMZRz\WG2bXXueEB4cXSqIH3leIZwem2rbh?= NU\5NIpNOjN2NUG4NVc>
K562 M2K1SGZ2dmO2aX;uJGF{e2G7 NI\4bmoxNjVizszN NVrFdmpMOjRiaB?= NWjVU3Nv\XSqYX7vcC=> NF3Oc2Rl\WO{ZXHz[ZMhfGinIHXufplu\SCjY4Tpeol1gSCxZjDISGFEeyClbz30doVifG2nboSge4l1cCCldYLjeY1qdg>? MUGyN|Q{ODl3Nx?=
HEL MmmxSpVv[3Srb36gRZN{[Xl? MlHWNE42KM7:TR?= NYe2emhROjRiaB?= Mon1[ZRp[W6xbB?= NUm0fnJY\GWlcnXhd4V{KHSqZTDlcpp6dWViYXP0bZZqfHlib3[gTGRCS3NiY3:teJJm[XSvZX70JJdqfGhiY4XyZ5VucW5? M4nvOVI{PDNyOUW3
HL60 MX;BdI9xfG:|aYOgRZN{[Xl? MXSxJO69VQ>? M3y5bFI1KGh? NHn3VlZqdmS3Y3XzxsBk\WyuIHTlZZRp MWeyN|QxODVzOR?=
KG1 NFj0cpNCeG:ydH;zbZMhSXO|YYm= MmnCNUDPxE1? MYqyOEBp NVT1WIpQcW6mdXPld:Kh[2WubDDk[YF1cA>? MmTGNlM1ODB3MUm=
Kazumi MoT6RZBweHSxc3nzJGF{e2G7 NIe3T4oyKM7:TR?= M1HzS|I1KGh? M3LnVIlv\HWlZYRCpINmdGxiZHXheIg> MUWyN|QxODVzOR?=
K562 MnvzRZBweHSxc3nzJGF{e2G7 MkHpNUDPxE1? MXWyOEBp MV;pcoR2[2W|wrDj[YxtKGSnYYTo MUOyN|QxODVzOR?=
THP1 M1jZfmFxd3C2b4Ppd{BCe3OjeR?= NUXuOo9vOSEQvF2= M4PKb|I1KGh? NY\wO2Z6cW6mdXPld:Kh[2WubDDk[YF1cA>? NXPTdVNlOjN2MEC1NVk>
SH-SY5Y NF7sSHpHfW6ldHnvckBCe3OjeR?= NHzkPVUzPTBibl2= M2nkZ|E3KGh? NVzxOW02[2ijbnfld{BmgHC{ZYPzbY9vKHCjdITldo4hd2ZiZ3Xu[ZMhcW64b3z2[YQhcW5iY3jvcIV{fGW{b3ygd5lvfGinc3nzMEB2eHSja3WgZY5lKGWoZnz1fC=> MViyN|MzPjR{Mh?=
HEK293 MkjxSpVv[3Srb36gRZN{[Xl? M1XMV|EhyrWPwrC= NVnlR4FpOThiaNMg NHO2TIFqdmirYnn0d{B1cGVia3HsbZJqdi15LX3l[IlifGWmIILlZ5J2cXSvZX70JI9nKHO7boDobYxqdi1zIHHn[5Jm\2G2ZYOgbY51dyCjZ3fy[ZNwdWW| M1X2d|I{Ojh2OES4
HTK NF;WcXdHfW6ldHnvckBCe3OjeR?= M3HRXVQxOCCwTR?= MmTYO|IhcA>? NWrWWINGcW6qaXLpeJMhXEeILd8y5qCUUW6mdXPl[EBOgW:oaXLyc4Jt[XO2IFTp[oZmemWwdHnheIlwdg>? MnfsNlMzQDRyMEK=
HTK MmrmSpVv[3Srb36gRZN{[Xl? NILGVmMyODBvOECwcm0> MWq3NkBp M3rhS4Jtd2OtczDUS2Yu|rMkgKPJcoR2[2WmIGLPV{BidmRiSELPNuKhSWOldX31cIF1cW:w M4TrRVI{Ojh2MECy
Caco-2  NGC2[2tHfW6ldHnvckBCe3OjeR?= NV7r[XpxOSEEtV5CpC=> NYjGVI9ZOjRiaB?= MorK[IVkemWjc3XzJHNGWlRicILveIVqdiCneIDy[ZN{cW:w M4\TVlI{OTl3MEew
HeLa NF7hZpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHu4SZkyODBibl2= Mnu3NlQhcA>? M4PY[WROW09? M3u5[mlEPTBib3[gNVAxdk1? NFjQdWIzOzF4NUe0PC=>
HeLa NGLBd3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX20NEBvVQ>? NUDBOWQ2PDhiaB?= MUPEUXNQ M4jabGlEPTBib3[gOFBvVQ>? M3LHOFI{OTZ3N{S4
HeLa MlXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TFZ|IxKG6P MVu3NkBp M{j4d2ROW09? M{\wV2lEPTBib3[gNlBvVQ>? NFjXUIIzOzF4NUe0PC=>
HeLa MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTrNVAwOzBxNUCgcm0> NHi3UFc4OiCq M4XJcGROW09? MWHpcoNz\WG|ZYOgeIhmKG63bXLldkBw\iCPTWCgLO6V|qivKTDsc5N{KGOnbHzzJIRwe2ViZHXw[Y5l\W62bIm= NF\LSGEzOzF4NUe0PC=>
MDA-MB-231 M1LNcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml[1NlUuPDByIH7N NVf5NHI3PDhiaB?= MUDJR|UxKG:oIEK2N{4zdk4EoB?= MkfxNlMxPTVzOUi=
MCF-7  NWe3eJY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTjNWZuOjVvNECwJI5O M4SwZVQ5KGh? M1zhOmlEPTBib3[gNlIxNjSwTR?= MorQNlMxPTVzOUi=
ECC-1  M1LOcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTCbYo4OTByIH7N M2SydVI1KGh? NEXXfXFmfGijbn;s M3;5TIlv[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBieG:ydH;0bYMhdnWlbHXpJJRwKDN3JR?= MYOyN|AzQDhyMx?=
HEC-1A MlTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHy2eWkyODBibl2= MVqyOEBp NHm3cIRmfGijbn;s M1fteolv[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBieG:ydH;0bYMhdnWlbHXpJJRwKDN7JR?= Ml;RNlMxOjh6MEO=
NHAC-kn MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17T[VExNzFyMD:1NFAhdk1? NEm3[4wyOiCq MnXNSG1UVw>? NY\pTVJsUUN3MDDv[kA2ODCwTR?= NHG2dVEzOzBzN{i3NS=>
A549 NYnSV3Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfrU4syOjVyIH7N MkHQOk04OiCq M3WwOGROW09? MWrjZZV{\XNiYTDndoVifGW{IHnubIljcXSxcomg[YZn\WO2IHPvcYJqdmVid3n0bEBVYFRib4Kg[ZJtd3Srbnni NEjoN2szOjl7NEe4NC=>
MG-63 M4XqSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33ZRlMxOCCwTR?= NX7obmJVOTJiaB?= MULEUXNQ MlvHbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFg3LQ>? MV6yNlc6QTN|OB?=
MG-63 NEX3cWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Lac|MxOCCwTR?= NHrhXFkzPCCq NFPBdVRFVVOR NVHRWGYzcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDZ5JR?= NEDndVYzOjd7OUOzPC=>
MG-63 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUmzNFAhdk1? M4rXUVQ5KGh? M1L0WmROW09? MnjPbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFU3LQ>? MU[yNlc6QTN|OB?=
HL60  NFvPNYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nmV|E2OC1|NUCgcm0> NGK3cFAzPCCq NWHnTFN3cW6lcnXhd4V{KGOnbHygZZBweHSxc3nzxsB4cGWwIHPvcoNmdnS{YYTpc45{KGirZ3jldkB1cGGwIEK1NEBvVQ>? NWTZRoZMOjJ5NUO3N|k>
U937 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LlUlE2OC1|NUCgcm0> MViyOEBp NVfjWXhpcW6lcnXhd4V{KGOnbHygZZBweHSxc3nzxsB4cGWwIHPvcoNmdnS{YYTpc45{KGirZ3jldkB1cGGwIEK1NEBvVQ>? MX6yNlc2Ozd|OR?=
SCC-6 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml20NlAxNTN{MECgcm0> MWmxNk8zPC92ODDo MYnEUXNQ MnGzbY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gc4YhW0OFLU[gZ4VtdHNiaX6gZUBld3OnLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NHLuOoQzOjV3MkOyNS=>
U87  NE\FZnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV:xNFAuOzByIH7n MnPKNlQhcA>? MWnpcohq[mm2czD0bIUh[2WubDDndo94fGhidH:gO|ImKCCjdDCyNFBv\w>? NFPSbJczOjJ5MEi0PS=>
K562 M{jheGZ2dmO2aX;uJGF{e2G7 M{jsNFEh|ryP M1nWOVEzKGh? M3jEd2ROW09? NHHzW29mdmijbnPld{B1cGViZYjwdoV{e2mxbjDv[kBTXU6[MzDpcoR2[2WmIHL5JFUu[XqjLVPkVi=> NH;oW|MzOjF5OUG5PC=>
Reh Ml[xSpVv[3Srb36gRZN{[Xl? M1fZbVAvOy9zIN88US=> NH3vbIgyOiCq MYXEUXNQ NILaUnpmdmijbnPld{B1cGViZYjwdoV{e2mxbjDv[kBTXU6[MzDpcoR2[2WmIHL5JFUu[XqjLVPkVi=> NXjSOWNvOjJzN{mxPVg>

... Click to View More Cell Line Experimental Data

In vivo試験 Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. [1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. [5]
臨床試験
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

In vitro HDAC activity Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×105 cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 106 cpm) of [3H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [3H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [3H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.

細胞アッセイ:

[1]

細胞株 MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3
濃度 Dissolved in absolute ethanol, final concentrations ~10 μM
反応時間 96 hours
実験の流れ

Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion.

動物実験:

[1]

動物モデル Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU
製剤 Dissolved in DMSO
投薬量 ~5 mg/kg/day
投与方法 Injection s.c.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Trichostatin A (TSA) SDF
分子量 302.4
化学式

C17H22N2O3

CAS No. 58880-19-6
保管 3年-20℃
2年-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 23 mg/mL (76.05 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80, pH 4 6 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (R,2E,4E)-6-(4-(dimethylamino)benzoyl)-N-hydroxy-4-methylhepta-2,4-dienamide

文献中の引用 (20)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related HDAC 阻害剤

  • LMK-235

    LMK-235は一種のHDAC4とHDAC5選択性阻害剤で、IC50値が11.9 nM と 4.2 nMに分かれます。

  • CAY10603

    CAY10603は一種の有効的で、選択性的なHDAC6阻害剤で、IC50値が2 pMになって、HDAC6に作用する選択性はHDACsに作用する選択性より200倍以上が高くなります。

  • 4SC-202

    4SC-202は一種の選択性I型HDAC阻害剤で、HDAC1、HDAC2とHDAC3に作用する時のIC50値が1.20 μM、1.12 μMと0.57 μMそれぞれに分かれて、Lysine specific demethylase 1 (LSD1)にも抑制活性を表します。臨床1期。

  • HPOB

    HPOBは一種の有効的で、選択性HDAC6阻害剤で、IC50値が56 nMになって、HDAC6に作用する選択性は他のHDACsに作用する選択性より30倍以上が高くなります。

  • Panobinostat (LBH589)

    Panobinostat (LBH589) は一種の新たで、広範なHDAC阻害剤で、無細胞試験でIC50値が5 nMです。臨床3期。

  • Vorinostat (SAHA, MK0683)

    Vorinostat (suberoylanilide hydroxamic acid, SAHA)は一種のHDAC阻害剤で、無細胞試験でIC50値が約10 nMです。

  • Entinostat (MS-275)

    Entinostat (MS-275)はHDAC1とHDAC3を強く抑制して、無細胞試験でIC50値が0.51μMと1.7μMに分かれて、抑制作用がHDACs 4/6/8/10より良くなリます。臨床3期。

  • Romidepsin (FK228, Depsipeptide)

    Romidepsin (FK228, Depsipeptide)は一種の有効なHDAC1とHDAC2阻害剤で、無細胞試験でIC50値が36 nMと47 nMに分かれます。

    Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.

  • RGFP966

    RGFP966は一種のHDAC3阻害剤で、無細胞試験でIC50値が0.08μMになって、HDAC3に作用する選択性が他のHDACに作用する選択性より200倍以上高くなります。

最近チェックしたアイテム

Tags: Trichostatin A (TSA)を買う | Trichostatin A (TSA)供給者 | Trichostatin A (TSA)を購入する | Trichostatin A (TSA)費用 | Trichostatin A (TSA)生産者 | オーダーTrichostatin A (TSA) | Trichostatin A (TSA)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ